Your browser doesn't support javascript.
loading
Longitudinal reduction in brain volume in patients with schizophrenia and its association with cognitive function.
Yamazaki, Ryuichi; Matsumoto, Junya; Ito, Satsuki; Nemoto, Kiyotaka; Fukunaga, Masaki; Hashimoto, Naoki; Kodaka, Fumitoshi; Takano, Harumasa; Hasegawa, Naomi; Yasuda, Yuka; Fujimoto, Michiko; Yamamori, Hidenaga; Watanabe, Yoshiyuki; Miura, Kenichiro; Hashimoto, Ryota.
Affiliation
  • Yamazaki R; Department of Pathology of Mental Diseases, National Institute of Mental Health, National Center of Neurology and Psychiatry, Kodaira, Japan.
  • Matsumoto J; Department of Psychiatry, The Jikei University School of Medicine, Tokyo, Japan.
  • Ito S; Department of Pathology of Mental Diseases, National Institute of Mental Health, National Center of Neurology and Psychiatry, Kodaira, Japan.
  • Nemoto K; Department of Pathology of Mental Diseases, National Institute of Mental Health, National Center of Neurology and Psychiatry, Kodaira, Japan.
  • Fukunaga M; Department of Developmental and Clinical Psychology, The Division of Human Developmental Sciences, Graduate School of Humanity and Sciences, Ochanomizu University, Tokyo, Japan.
  • Hashimoto N; Department of Psychiatry, Institute of Medicine, University of Tsukuba, Tsukuba, Japan.
  • Kodaka F; Section of Brain Function Information, National Institute for Physiological Sciences, Okazaki, Japan.
  • Takano H; Department of Psychiatry, Hokkaido University Graduate School of Medicine, Sapporo, Japan.
  • Hasegawa N; Department of Pathology of Mental Diseases, National Institute of Mental Health, National Center of Neurology and Psychiatry, Kodaira, Japan.
  • Yasuda Y; Department of Psychiatry, The Jikei University School of Medicine, Tokyo, Japan.
  • Fujimoto M; Department of Clinical Neuroimaging, Integrative Brain Imaging Center, National Center of Neurology and Psychiatry, Kodaira, Japan.
  • Yamamori H; Department of Pathology of Mental Diseases, National Institute of Mental Health, National Center of Neurology and Psychiatry, Kodaira, Japan.
  • Watanabe Y; Department of Pathology of Mental Diseases, National Institute of Mental Health, National Center of Neurology and Psychiatry, Kodaira, Japan.
  • Miura K; Life Grow Brilliant Mental Clinic, Medical Corporation Foster, Osaka, Japan.
  • Hashimoto R; Department of Pathology of Mental Diseases, National Institute of Mental Health, National Center of Neurology and Psychiatry, Kodaira, Japan.
Neuropsychopharmacol Rep ; 44(1): 206-215, 2024 Mar.
Article in En | MEDLINE | ID: mdl-38348613
ABSTRACT
Establishing a brain biomarker for schizophrenia is strongly desirable not only to support diagnosis by psychiatrists but also to help track the progressive changes in the brain over the course of the illness. A brain morphological signature of schizophrenia was reported in a recent study and is defined by clusters of brain regions with reduced volume in schizophrenia patients compared to healthy individuals. This signature was proven to be effective at differentiating patients with schizophrenia from healthy individuals, suggesting that it is a good candidate brain biomarker of schizophrenia. However, the longitudinal characteristics of this signature have remained unclear. In this study, we examined whether these changes occurred over time and whether they were associated with clinical outcomes. We found a significant change in the brain morphological signature in schizophrenia patients with more brain volume loss than the natural, age-related reduction in healthy individuals, suggesting that this change can capture a progressive morphological change in the brain. We further found a significant association between changes in the brain morphological signature and changes in the full-scale intelligence quotient (IQ). The patients with IQ improvement showed preserved brain morphological signatures, whereas the patients without IQ improvement showed progressive changes in the brain morphological signature, suggesting a link between potential recovery of intellectual abilities and the speed of brain pathology progression. We conclude that the brain morphological signature is a brain biomarker that can be used to evaluate progressive changes in the brain that are associated with cognitive impairment due to schizophrenia.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Schizophrenia Type of study: Risk_factors_studies Limits: Humans Language: En Journal: Neuropsychopharmacol Rep / Neuropsychopharmacol. rep / Neuropsychopharmacology reports Year: 2024 Document type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Schizophrenia Type of study: Risk_factors_studies Limits: Humans Language: En Journal: Neuropsychopharmacol Rep / Neuropsychopharmacol. rep / Neuropsychopharmacology reports Year: 2024 Document type: Article